Site Reference ID/Investigator# 13441
Orlando, Florida, 32809, United States
NCT Number: NCT00826358
The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Orlando, Florida, 32809, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once, please see Arm Description for more details.
Once, see Arm Description for more detail
once, see Arm Description for more detail
Time frame: 7 days
Time frame: 7 days
AstraZeneca
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06429137
Healthy
Biberach, Germany
View Trial DetailsNCT01520792
Healthy
Clermont-Ferrand, France
View Trial DetailsNCT07542886
Healthy
Brussels, Bruxelles-capitale, Région de, Belgium
View Trial DetailsNCT02206178
Healthy
Clermont-Ferrand, France
View Trial Details